Pasteurella multocida

(aka Pasteurella canis)

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Pasteurella multocida, (aka Pasteurella canis), is a Gram-negative, non-spore-forming, aerobic, non-motile, coccobacillus bacterium. It has been detected in at least 4 gut microbiome compilation studies or metastudies. The DNA G+C content is 40.8-43.9%. Pasteurella multocida is probably a rare gut coloniser. (Christensen2004; Mutters2005Bergey; Mutters1985)



  • This organism has been recovered from many animal and human infections. The risk classification (www.baua.de) for this organism is 2, i.e., risk of individual infection, but low risk of spread (notes: zoonotic pathogen). Is a known human pathogen. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Christensen2004); (Mutters2005Bergey); (Mutters1985);
    Character Response
  • 🌡
  • Temperature tolerance:
  • grows at 25℃; grows at 42℃; Grows optimally at 36-42℃.
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; galactose; glucose; mannose; ribose; sucrose; mannitol; sorbitol;
  • ±
  • Strain-dependent acid from carbs:
  • D-arabinose; fucose; xylose; trehalose; glycerol;
  • Active enzymes:
  • catalase; ornithine decarboxylase; oxidase;
  • ±
  • Strain-dependent active enzymes:
  • α-glucosidase;
    • SPECIAL FEATURES (Mutters2005Bergey); (Mutters1985);
    Character Response
  • ✓
  • Metabolites produced:
  • indole;
  • ✗
  • Metabolites not produced:
  • H₂S;
  • ✗
  • VP test:
  • not active
  • ✗
  • ONPG test:
  • not active
  • ✗
  • Haemolysis:
  • absent
  • ✓
  • Nitrate:
  • reduced
  • ✗
  • Nitrite:
  • not reduced
  • ✗
  • Pigments:
  • not produced
    • RESPONSE TO ANTIBIOTICS (Goldstein2018); (Goldstein2017); (Goldstein2012); (Goldstein2000); (Goldstein1999a);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; ampicillin-sulbactam; ertapenem; meropenem; oxacillin; penicillin; penicillin G; piperacillin-tazobactam;
  • Cephalosporins:
  • cefalexin; cefazolin;
  • Macrolides:
  • azithromycin; erythromycin;
  • Tetracyclines:
  • doxycycline; minocycline; tetracycline; tigecycline;
  • Quinolines:
  • ciprofloxacin; garenoxacin; gatifloxacin; levofloxacin; moxifloxacin; sparfloxacin; trovafloxacin;
  • Heterocycles:
  • trimethoprim-sulfamethoxazole;
  • Miscellaneous antibiotics:
  • clindamycin;

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Gammaproteobacteria Order:  Pasteurellales Family:  Pasteurellaceae Genus:  Pasteurella Alt. name:  Pasteurella canis Gram stain:  neg O2 Relation.:  aerobic Spore:  No spore Motility:  Sessile Morphology:  Coccobacillus Pigment:  neg
    Health:  Unknown
    Source:  many animal and human infections
    DNA G+C(%):  40.8-43.9
    Opt. T:  36-42℃
    Lower T(℃):  25(+)
    High T(℃):  42(+)
    		Urea:  neg Gelatin:  neg Tween:  20(neg) 80(neg)
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    D-Arabinose:  d L-Arabinose:  neg Fructose:  + Fucose:  d D-Fucose:  neg Galactose:  + Glucose:  + Mannose:  + Rhamnose:  neg Ribose:  + Sorbose:  neg Xylose:  d L-Xylose:  neg Cellubiose:  neg Gentiobiose:  neg Lactose:  neg Maltose:  neg Melezitose:  neg Melibiose:  neg Sucrose:  + Trehalose:  d Turanose:  neg Amygdalin:  neg Aesculin:  neg Glycogen:  neg Inulin:  neg Adonitol:  neg D-Arabitol:  neg Dulcitol:  neg Erythritol:  neg Glycerol:  d Inositol:  neg Mannitol:  + Sorbitol:  + Xylitol:  neg Arbutin:  neg Salicin:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Citrate:  neg Malonate:  neg Mucate:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  + Catalase:  + Urease:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  d β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg Xylosidase:  neg ArgDH:  neg LysDC:  neg OrnDC:  + Phe deaminase:  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		H2S:  neg Indole:  + Pigment:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    Augmentin:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.06–0.25)
    amp-sulb:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.015–0.125)
    oxacillin:  S(MIC50): 1, MIC90: 8, RNG: (0.06->64)
    penicillin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.03–0.125)
    penicillin_G:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.03–0.125)
    piper-taz:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.03)
    ertapenem:  S(MIC50): 0.015, MIC90: 0.015, RNG: (0.015–0.03)
    meropenem:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.03)
    cefalexin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.06-2)
    cefazolin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.06–1)
    azithromycin:  S(MIC50): 0.25, MIC90: 1, RNG: (0.03–1)
    erythromycin:  S(MIC50): 2, MIC90: 2, RNG: (0.25–2)
    ciprofloxacin:  S(MIC50): 0.016, MIC90: 0.016, RNG: (0.004–0.03)
    garenoxacin:  S(MIC50): 0.008, MIC90: 0.008, RNG: (0.001–0.015)
    gatifloxacin:  S(MIC50): 0.016, MIC90: 0.016, RNG: (0.008–0.03)
    levofloxacin:  S(MIC50): 0.016, MIC90: 0.03, RNG: (0.008–0.03)
    moxifloxacin:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.06)
    sparfloxacin:  S(MIC50): 0.008, MIC90: 0.008, RNG: (0.004–0.008)
    trovafloxacin:  S(MIC50): 0.016, MIC90: 0.016, RNG: (0.008–0.03)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.05–0.25)
    minocycline:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.06–0.125)
    tetracycline:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.06–8)
    tigecycline:  S(MIC50): 0.03, MIC90: 0.03, RNG: (0.03–0.03)
    SXT:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.015–0.125)
    clindamycin:  R(MIC50): 16, MIC90: 16, RNG: (4–>16)

    References

    SPECIFIC REFERENCES FOR PASTEURELLA MULTOCIDA
  • Christensen2004 - Revised description and classification of atypical isolates of Pasteurella multocida from bovine lungs based on genotypic characterization to include variants previously classified as biovar 2 of Pasteurella canis and Pasteurella avium.
  • Mutters2005Bergey - Bergey's manual of systematic bacteriology. Vol. 2, The Gammaproteobacteria Part B. Family Pasteurellaceae, Genus I. Pasteurella
  • Goldstein2018 - Comparative In Vitro Activity of Omadacycline against Dog and Cat Bite Wound Isolates.
  • Goldstein2017 - In Vitro Activity of Pexiganan and 10 Comparator Antimicrobials against 234 Isolates, Including 93 Pasteurella Species and 50 Anaerobic Bacterial Isolates Recovered from Animal Bite Wounds.
  • Goldstein2012 - Ceftaroline versus isolates from animal bite wounds: comparative in vitro activities against 243 isolates, including 156 Pasteurella species isolates.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • Goldstein1999a - Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
  • Mutters1985 - Reclassification of the Genus Pasteurella Trevisan 1887 on the Basis of Deoxyribonucleic Acid Homology, with Proposals for the New Species Pasteurella dagmatis, Pasteurella canis, Pasteurella stomatis, Pasteurella anatis, and Pasteurella langaa
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PASTEURELLA MULTOCIDA
  • De2020 - Metagenomic analysis of gut microbiome and resistome of diarrheal fecal samples from Kolkata, India, reveals the core and variable microbiota including signatures of microbial dark matter.
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: January 14, 2022